Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia

This study is currently recruiting participants.
Verified April 2012 by Samsung Medical Center
Sponsor:
Information provided by (Responsible Party):
Gaab Soo Kim, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01379352
First received: June 21, 2011
Last updated: April 1, 2012
Last verified: April 2012

June 21, 2011
April 1, 2012
June 2011
May 2012   (final data collection date for primary outcome measure)
  • vecuronium requirements during preanhepatic phase [ Time Frame: during prehepatic phase of liver transplantation ] [ Designated as safety issue: No ]
    total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during preanhepatic phase
  • vecuronium requirements during anhepatic phase [ Time Frame: during anhepatic phase of liver transplantation ] [ Designated as safety issue: No ]
    total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during anhepatic phase
  • vecuronium requirements during neohepatic phase [ Time Frame: during neohepatic phase of liver transplantation ] [ Designated as safety issue: No ]
    total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during neohepatic phase
Same as current
Complete list of historical versions of study NCT01379352 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia
Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia

The vecuronium requirements may be reduced for recipients of living donor liver transplantation, as the vecuronium is eliminated principally by the liver. Furthermore, the requirements may be different according to the phase of surgery. The requirements may also be different according to the preoperative hepatic function as measured by MELD score during prehepatic phase, or graft to recipient body weight ratio (GRWR) during neohepatic phase. Therefore, the investigators are trying to investigate the difference of vecuronium requirements according to the phase of surgery or MELD score, GRWR.

The vecuronium requirements may be reduced for recipients of living donor liver transplantation, as the vecuronium is eliminated principally by the liver. Furthermore, the requirements may be different according to the phase of surgery. The requirements may by further reduced during anhepatic phase of liver transplantation. And the requirements may be increased as the graft functions during neohepatic phase.

We also postulated that the requirements may be different according to the preoperative hepatic function during preanhepatic phase, and according to the graft to recipient body weight ratio (GRWR) during neohepatic phase.

Therefore, we are trying to investigate the difference of vecuronium requirements according to the phase of surgery, MELD score, GRWR.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients undergoing elective living donor liver transplantation

Liver Transplantation
Not Provided
  • High MELD group
    Preoperative MELD score greater than 20
  • Low MELD group
    Preoperative MELD score lesser than 20
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
70
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients undergoing elective living donor liver transplantation

Exclusion Criteria:

  • patients who can not undergo train-of-four test due to central or peripheral neuromuscular disease.
  • patients with severe cardiopulmonary diseases.
  • patients who received transfusion with more than 10 units of packed red blood cells.
  • primary non-functioning graft immediately after reperfusion of the graft.
  • patients who administered drugs that influences the metabolism of vecuronium (such as anticonvulsant: phenytoin, carbamazepine, primidone, sodium valproate)
  • patients undergoing cadaver donor liver transplantation
Both
20 Years to 69 Years
No
Contact: Gaab Soo Kim, M.D.,Ph.D. 82-2-3410-2470 Gaabsoo.kim@samsung.com
Contact: Won Ho Kim, M.D. 82-2-3410-2470 bullet57@naver.com
Korea, Republic of
 
NCT01379352
2011-04-015
No
Gaab Soo Kim, Samsung Medical Center
Samsung Medical Center
Not Provided
Study Director: Gaab Soo Kim, M.D.,Ph.D. Samsung Medical Center
Samsung Medical Center
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP